Literature DB >> 18212769

Clinical and pathologic aspects of basal-like breast cancers.

Oluwole Fadare1, Fattaneh A Tavassoli.   

Abstract

Gene-expression profiling of breast cancers has shown that distinct molecular subclasses are present within tumors that are apparently morphologically similar. The molecular subclasses of cohorts classified by the 'intrinsic' gene set include the luminal A and B, erbB-2+, normal-breast-like, and basal-like tumors. Basal-like breast cancers have been reported to be associated with worse overall and disease-free survival compared with the luminal A subtype. In addition, there is an immunohistochemical surrogate for the basal-like profile, which has considerably facilitated their study in non-specialty laboratories. Basal-like breast carcinomas have markedly reduced expression of genes related to estrogen receptors and erbB-2, and express proteins that are characteristic of the normal myoepithelial cell. This Review appraises the current state of knowledge on the clinical and pathologic features of breast cancers classified as 'basal-like' by gene-expression profiling and/or immunohistochemical criteria. These tumors seem to be relatively heterogeneous according to a multitude of clinicopathologic parameters, which indicates that their most prognostically relevant subsets have yet to be defined. Similarly to tumors of luminal epithelial differentiation, carcinomas of the 'basal' type have a spectrum of morphologic and clinical characteristics.

Entities:  

Mesh:

Year:  2008        PMID: 18212769     DOI: 10.1038/ncponc1038

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  37 in total

1.  Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

Authors:  Maria J Sambade; Randall J Kimple; J Terese Camp; Eldon Peters; Chad A Livasy; Carolyn I Sartor; Janiel M Shields
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

Review 2.  Inflammation fuels tumor progress and metastasis.

Authors:  Jingyi Liu; Pengnian Charles Lin; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Breast cancer subtypes: morphologic and biologic characterization.

Authors:  Shahla Masood
Journal:  Womens Health (Lond)       Date:  2016-01-12

4.  Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells.

Authors:  Dan Su; Xiaoying Fu; Songqing Fan; Xiao Wu; Xin-Xin Wang; Liya Fu; Xue-Yuan Dong; Jianping Jenny Ni; Li Fu; Zhengmao Zhu; Jin-Tang Dong
Journal:  Am J Pathol       Date:  2012-03       Impact factor: 4.307

5.  Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.

Authors:  Andrey I Khramtsov; Galina F Khramtsova; Maria Tretiakova; Dezheng Huo; Olufunmilayo I Olopade; Kathleen H Goss
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

6.  Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Authors:  Elizabeth Tarasewicz; Lisbi Rivas; Randala Hamdan; Danijela Dokic; Vamsi Parimi; Beatriz Penalver Bernabe; Alexandra Thomas; Lonnie D Shea; Jacqueline S Jeruss
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  CrkII transgene induces atypical mammary gland development and tumorigenesis.

Authors:  Kelly E Fathers; Sonia Rodrigues; Dongmei Zuo; Indrani Vasudeva Murthy; Michael Hallett; Robert Cardiff; Morag Park
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

9.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Authors:  Alfonso Sánchez-Muñoz; Elena Gallego; Vanessa de Luque; Luís G Pérez-Rivas; Luís Vicioso; Nuria Ribelles; José Lozano; Emilio Alba
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

10.  Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors.

Authors:  Pia Boström; Mirva Söderström; Tuire Palokangas; Tero Vahlberg; Yrjö Collan; Olli Carpen; Pirkko Hirsimäki
Journal:  BMC Res Notes       Date:  2009-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.